Long-term therapy of chronic hepatitis B with lamivudine. - Wikidata - awgldk - TriplyDB

Long-term therapy of chronic hepatitis B with lamivudine.

Long-term therapy of chronic hepatitis B with lamivudine.

http://www.wikidata.org/entity/Q54035757

about

Entecavir for chronic hepatitis B Entecavir for chronic hepatitis B High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial.Liver transplantation for viral hepatitis in 2015 Clinical utility of entecavir for chronic hepatitis B in Chinese patients Viral quasispecies evolution Direct acting antivirals for the treatment of chronic viral hepatitis Combination of small interfering RNAs mediates greater suppression on hepatitis B virus cccDNA in HepG2.2.15 cells Recent advances in micro/nanotechnologies for global control of hepatitis B infection Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection.Evaluation of transcriptional efficiency of hepatitis B virus covalently closed circular DNA by reverse transcription-PCR combined with the restriction enzyme digestion method Novel approaches towards conquering hepatitis B virus infection.Clinical efficacy of a 24-months course of lamivudine therapy in patients with HBeAg negative chronic hepatitis B: a long-term prospective study.Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection.Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.Management of viral hepatitis B.Clinical significance of hepatitis B e antigen level measurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive.Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.Genomic analysis of anti-hepatitis B virus (HBV) activity by small interfering RNA and lamivudine in stable HBV-producing cells.Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil.Diagnosis and management of pre-core mutant chronic hepatitis B.Current status of antiviral therapy for hepatitis B Evolving therapies for the treatment of chronic hepatitis B virus infection.A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B.Chronic hepatitis B: current and future treatment options.Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.Probing rate of YMDD motif mutant in lamivudine treatment of Iranian patients with chronic hepatitis B virus infection.Antiviral treatment of patients with HBV-related cirrhosis.Effect of lamivudine in HBeAg-positive chronic hepatitis B: discordant effect on HBeAg and HBV DNA according to pretreatment ALT level Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era.HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya.Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak Review article: current management of chronic hepatitis B.Prophylactic Effect of Lamivudine for Chemotherapy-Induced Hepatitis B Reactivation in Breast Cancer: A Meta-Analysis Adefovir dipivoxil in the treatment of chronic hepatitis B.Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy.Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.

P2860

Q24195119-CACA2130-C8B3-45C9-9156-5E6201EE36AA Q24244842-1D2C19BD-E468-406B-8FCA-7504BE873631 Q24814210-4AD3EE4F-4F3B-4E80-BE57-1D8A0F9C87E7 Q26773224-BF1CC70C-169B-4F62-9719-303591149440 Q26830371-38F6D187-A8B2-4062-B83D-BA7D66F5039F Q27013917-1233ABD0-ECBC-4C84-8940-E9147F995FCA Q27022216-A9CCB168-70B5-49C8-A140-E69AF8303C9D Q27489094-3F678D13-42F7-4F9D-8DDF-027DBC977424 Q30394611-A3B2A4BE-F719-4535-B3E2-4DD1C1F85B3A Q33631739-A35E126B-0CCE-4EA7-ADFA-57B07452A100 Q33716406-43BF41DB-6FA6-46E1-B016-5A015554FC92 Q33787687-480FC7C9-185B-44B9-9BF1-5535BE1B8792 Q33879651-DBF2C9CC-B4B8-4EB8-9AA3-AE305048226F Q33883722-2180B826-E2EF-41D5-9DB8-689434BC8AAC Q33939443-2BEC1BDA-B79C-4144-83F0-7EC3C0B64B79 Q33959006-F150C3CA-BAFE-40CD-9863-E8F8E92A37D0 Q34017787-FDD00DA0-D3AC-4734-A366-A3407E89DE90 Q34017814-849920B0-6F18-4DEA-BAC3-9E40A10681DD Q34109170-928FD787-D18C-4AD5-9D68-9649C09743FB Q34123971-2ED221EC-684E-4932-B4E4-A35D7E93B9E6 Q34233156-72D582D1-9464-4ABF-89B9-582F142705E0 Q34330228-B481F49B-42B5-49BC-B1A7-1CED61808F68 Q34368364-25B06007-066D-485B-98F2-ABA919A4582D Q34408879-62AEF733-B34C-4D4B-BA18-49D722EF8C6C Q34519117-9DCAFB12-75EB-4C2C-B966-ACE19C095F50 Q34604857-142DF168-9258-4297-80F3-40E6C20C508B Q34687438-F185FDBA-FEAA-4EB2-AD23-B2FDDC5BD6BC Q34700034-3CA1B518-B6CE-4B67-9874-E043A5631D13 Q34756218-8BC45780-B622-4A43-8F4E-11F06CC7DE13 Q34862728-F67EAC62-E623-425F-B8FE-52B39A98C910 Q35020817-853EEDEB-620B-456A-8F32-F248D1498DB6 Q35045329-CB87A912-C7CA-4AC4-893B-A0E42B8362D1 Q35076630-BEDFAFE8-C579-4190-B4C3-2931BE5C17EC Q35224111-49D7D12D-EB7E-45F0-BCB2-746CB95BC0E4 Q35598919-24EC9B22-A0DC-4A93-A24E-A188125A6B30 Q35612108-FA6F99A9-AEB8-4DAB-8D18-F7DA2D460D32 Q35658261-A609DF24-05AC-44D0-8688-CA6B55E7B015 Q35678267-6977D1F8-76BA-4374-B6D8-D8D23615574F Q35735964-395DD4EA-EF9E-4A5C-9DD6-699A1CF53514 Q35806182-791082DE-75CE-470B-9519-23075811AF15

P2860

Long-term therapy of chronic hepatitis B with lamivudine.

http://www.wikidata.org/entity/Q54035757

description

2000 nî lūn-bûn

@nan

2000年の論文

@ja

2000年学术文章

@wuu

2000年学术文章

@zh

2000年学术文章

@zh-cn

2000年学术文章

@zh-hans

2000年学术文章

@zh-my

2000年学术文章

@zh-sg

2000年學術文章

@yue

2000年學術文章

@zh-hant

name

Long-term therapy of chronic hepatitis B with lamivudine.

@en

Long-term therapy of chronic hepatitis B with lamivudine.

@nl

type

label

Long-term therapy of chronic hepatitis B with lamivudine.

@en

Long-term therapy of chronic hepatitis B with lamivudine.

@nl

prefLabel

Long-term therapy of chronic hepatitis B with lamivudine.

@en

Long-term therapy of chronic hepatitis B with lamivudine.

@nl

P1433

Q54035757-D9F95175-FBFF-4D7E-A122-521C7B7221BE

P1476

Q54035757-86D56153-B98A-469A-A2BE-123B2E8B4183

P2093

Q54035757-2E44657B-A254-4E73-9046-C029F311A967

Q54035757-51AB2C6A-0B65-4786-A177-1E7A76CA9958

Q54035757-6F2CFC3C-8296-422E-8B69-22FEE14B0B45

Q54035757-7DB112C7-94BD-428C-8329-B004444E8AC8

Q54035757-92F3EEF8-6C39-44B3-9D64-96B06E8CB50A

Q54035757-956ED891-CFB0-4526-9432-770FEFF310A2

Q54035757-9BBB16A1-AC26-40C0-AF19-47393A4236A6

Q54035757-ABA84E92-E17E-449D-8FE3-016C2E6B697C

Q54035757-B73A7341-5864-452A-9B0D-F6B8B58F7900

Q54035757-C9504061-5118-4EB0-9D5D-5FBCCE685B84

P304

Q54035757-EA66DAF6-FA05-4693-89E2-51C950B5A007

P31

Q54035757-C3FEF632-93AD-444D-8274-02A9B3990A56

P356

Q54035757-48C0A57F-29DA-482F-A3E7-EA2D7BA4FE2C

P407

Q54035757-C20D216F-F79F-4C8E-B99A-F2B4CC2B1848

P433

Q54035757-58AE89DE-EDF2-4B78-8D23-58C2844F7CFB

P478

Q54035757-4DED3FCF-7181-41A1-842E-E26E45FF0824

P577

Q54035757-C112216B-4202-42A0-9931-27AFE31512FF

P5875

Q54035757-2B085109-4316-4C96-B775-F99C10923788

P698

Q54035757-64AF6CA2-FEFD-4823-8A66-244429D0C913

P356

JHEP.2000.17912

P1433

P1476

Long-term therapy of chronic hepatitis B with lamivudine.

@en

P2093

Condreay LD

http://www.w3.org/2001/XMLSchema#string

Doo E

http://www.w3.org/2001/XMLSchema#string

Gauthier J

http://www.w3.org/2001/XMLSchema#string

Ghany MG

http://www.w3.org/2001/XMLSchema#string

Herion D

http://www.w3.org/2001/XMLSchema#string

Hoofnagle JH

http://www.w3.org/2001/XMLSchema#string

Khokhar MF

http://www.w3.org/2001/XMLSchema#string

Kleiner DE

http://www.w3.org/2001/XMLSchema#string

Kuhns MC

http://www.w3.org/2001/XMLSchema#string

Lau DT

http://www.w3.org/2001/XMLSchema#string

P304

828-834

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/JHEP.2000.17912

http://www.w3.org/2001/XMLSchema#string

P407

P433

4 Pt 1

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2000-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12319207

http://www.w3.org/2001/XMLSchema#string

P698

11003630

http://www.w3.org/2001/XMLSchema#string